Caribou Biosciences (CRBU) Stock Price, News & Analysis

Company Overview

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies.

Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.

Key Stats

• Today's Range: $1.93 to $1.97
• 50-Day Range: $1.71 to $2.36
• 52-Week Range: $0.73 to $3.54
• Volume: 300,675 shs
• Average Volume: 1.27 million shs
• Market Capitalization: $191.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Moderate Buy

Caribou Biosciences Stock Analysis - MarketRank™

Caribou Biosciences scored higher than 38% of companies evaluated by MarketBeat, and ranked 642nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Caribou Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Caribou Biosciences has a consensus price target of $8.00, representing about 309.2% upside from its current price of $1.96.

Amount of Analyst Coverage

Caribou Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.30) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Caribou Biosciences is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Caribou Biosciences is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Caribou Biosciences has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.64% of the float of Caribou Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Caribou Biosciences has a short interest ratio ("days to cover") of 5.49.

Change versus previous month

Short interest in Caribou Biosciences has recently increased by 4.57%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Caribou Biosciences does not currently pay a dividend.

Dividend Growth

Caribou Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Caribou Biosciences this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for CRBU on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Caribou Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,454.00 in company stock.

Percentage Held by Insiders

8.54% of the stock of Caribou Biosciences is held by insiders.

Percentage Held by Institutions

77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRBU Stock Analysis - Frequently Asked Questions

How have CRBU shares performed this year?

Caribou Biosciences' stock was trading at $1.59 on January 1st, 2026. Since then, CRBU stock has increased by 23.0% and is now trading at $1.9550.

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) released its quarterly earnings results on Thursday, March, 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.05. The company earned $3.94 million during the quarter, compared to analysts' expectations of $1.96 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 78.40% and a negative net margin of 1,327.40%.

When did Caribou Biosciences IPO?

Caribou Biosciences (CRBU) raised $285 million in an initial public offering on Wednesday, July 21st 2021. The company issued 19,000,000 shares at a price of $14.00-$16.00 per share.

Who are Caribou Biosciences' major shareholders?

Top institutional investors of Caribou Biosciences include Westmount Partners LLC (0.02%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Ruhi Ahmad Khan, Timothy P Kelly, Tina M Albertson and Sriram Ryali.
View institutional ownership trends.

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Caribou Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRBU
• CIK: 1619856
• Web: cariboubio.com
• Phone: 510-982-6030
• Fax: N/A
• Employees: 100
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Caribou Biosciences: $8.00
• High Price Target: $9.00
• Low Price Target: $7.00
• Potential Upside/Downside: +311.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$148.12 million
• Net Margins: -1,327.40%
• Pretax Margin: -1,332.33%
• Return on Equity: -78.40%
• Return on Assets: -58.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.71
• Quick Ratio: 5.71

Sales & Book Value

• Annual Sales: $11.16 million
• Price / Sales: 17.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.31 per share
• Price / Book: 1.48

Miscellaneous

• Outstanding Shares: 98,680,000
• Free Float: 90,255,000
• Market Cap: $191.93 million
• Optionable: Optionable
• Beta: 2.27